Sai Life Sciences ₹3,043-Cr IPO: Should You Subscribe or Avoid? - Read Now
The much-awaited Sai Life Sciences IPO opened for public subscription on December 11, 2024. With a price band of ₹522 to ₹549 per equity share, the ₹3,043 crore issue includes a fresh equity issuance worth ₹950 crore and an Offer for Sale (OFS) of up to 3.81 crore equity shares by promoters and investors.
The IPO aims to raise funds for repaying outstanding debts and supporting general corporate purposes. Retail investors can bid in lots of 27 shares, requiring a minimum investment of ₹14,823. The subscription window closes on December 13, 2024.
Sai Life Sciences IPO GMP: Early Indicators of Market Sentiment
The grey market premium (GMP) for Sai Life Sciences stands at ₹31 as of Day 1, reflecting moderate investor interest. Based on the upper price band of ₹549, the stock's expected listing price is ₹580, indicating a premium of approximately 6%. While GMP is a useful metric, actual market performance may vary.
Key Details of Sai Life Sciences IPO
1. IPO Size and Components
The ₹3,043 crore issue includes:
- Fresh equity worth ₹950 crore.
- Offer for Sale (OFS) of 3.81 crore shares by promoters and existing shareholders.
2. Allotment and Listing
The share allotment date is December 16, 2024. Refunds for unsuccessful bidders will also be processed on the same day. Sai Life Sciences shares are expected to list on the NSE and BSE on December 18, 2024.
3. Objectives of the Issue
The IPO proceeds will primarily be used to repay or prepay outstanding debts and for general corporate purposes.
4. Financial Highlights
Sai Life Sciences has demonstrated robust growth, with profit after tax (PAT) increasing from ₹6.23 crore in FY22 to ₹82.81 crore in FY24. The company recorded a PAT margin of 5.65% in FY24, a significant improvement over previous years.
Should You Apply for Sai Life Sciences IPO? Expert Opinions
Analysts have mixed views on the Sai Life Sciences IPO due to its high valuation and growth potential in the contract research and manufacturing segment (CRDMO).
Positive Views
- Growth Potential: The global CRDMO market is projected to grow to $159 billion by 2028, providing a favorable landscape for Sai Life Sciences.
- Strategic Strengths: The company’s regulatory approvals, skilled workforce, and cost-effective operations make it well-positioned to capitalize on industry trends.
- Strong Performance: StoxBox’s research analyst Palak Devadiga highlighted the company’s PAT growth and sectoral tailwinds as reasons to invest.
Concerns and Risks
- Valuation Concerns: At a P/E ratio of 138x, some analysts, like DRChoksey FinServ, believe the IPO is overpriced compared to its industry peers.
- Operational Risks: High infrastructure costs, reliance on key clients, and limited diversification pose challenges to long-term profitability.
Analyst Recommendations for Sai Life Sciences IPO
-
DRChoksey FinServ:
Assigns an "Avoid" rating due to stretched valuations and operational risks, despite growth prospects. -
StoxBox:
Recommends "Subscribe" for medium to long-term investment, citing strong financials and favorable industry trends. -
VLA Ambala (Stock Market Today):
Suggests applying for the IPO and holding shares for long-term gains, given the company’s robust growth trajectory and strategic objectives.
Sai Life Sciences Business Overview
Founded as a global contract research, development, and manufacturing organization (CRDMO), Sai Life Sciences provides end-to-end services across drug discovery, development, and manufacturing. With a portfolio serving over 280 clients, including 18 of the top 25 global pharmaceutical firms, the company is strategically positioned in the growing Indian and global CRDMO markets.
Should You Subscribe to Sai Life Sciences IPO?
The Sai Life Sciences IPO offers a compelling growth story backed by rising demand in the CRDMO segment. However, the stretched valuation and operational risks may deter short-term investors seeking quick returns.
For those with a long-term investment horizon, the company’s strong financial performance, strategic capabilities, and favorable market conditions make this IPO worth considering.
Also Read: MobiKwik ₹572 Crore IPO Live: Should You Subscribe? - Everything You Need To Know